Valuation: HLS Therapeutics Inc.

Market Cap 92.48M 80.85M 74.3M 69.25M 131M 8.81B 133M 892M 347M 4.33B 347M 340M 14.92B P/E 2026 *
-14.8x
P/E 2027 * -98.6x
Enterprise Value 92.48M 80.85M 74.3M 69.25M 131M 8.81B 133M 892M 347M 4.33B 347M 340M 14.92B EV / Sales 2026 *
1.59x
EV / Sales 2027 * 1.44x
Free-Float
99.47%
Yield 2026 *
-
Yield 2027 * -
1 day-1.18%
1 week+1.45%
Current month-4.76%
1 month-5.08%
3 months-4.55%
6 months-13.40%
Current year-12.86%
1 week 4
Extreme 4
4.41
1 month 4
Extreme 4
5.25
Current year 4
Extreme 4
5.25
1 year 4
Extreme 4
5.76
3 years 3
Extreme 3
7.12
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Compliance Officer 45 07/05/2018
Director TitleAgeSince
Chairman 48 22/06/2023
Director/Board Member 61 22/06/2023
Director/Board Member 58 01/05/2023
Date Insider Type Main position Quantity % Market Cap.
06-17Buy

Chief Executive Officer

2,000 0.0064%
06-16Buy

Chief Financial Officer

4,000 0.0128%
04-02Option

Director

3,976 0.0127%
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%+1.45%-14.98%-36.36% 92.48M
+2.37%+2.98%+9.31%+86.86% 92.06B
+0.51%+0.43%+44.87%+152.61% 55.96B
+2.20%+0.72%-7.31%+236.14% 22.26B
+1.26%+5.43%-10.09%-24.81% 8B
+1.90%+13.78%-26.29%-30.76% 7.76B
+1.89%+6.02%-9.61%-30.25% 6.66B
-2.66%+2.67%+21.60%+33.33% 6.35B
+0.17%+0.88%-2.65%+21.18% 5.36B
+1.86%+6.93%-5.00%-8.21% 3.63B
Average +0.83%+2.62%-0.01%+39.97% 20.81B
Weighted average by Cap. +1.56%+2.45%+14.22%+103.04%

Financials

2026 *2027 *
Net sales 58.03M 50.73M 46.62M 43.46M 82.42M 5.53B 83.67M 560M 218M 2.72B 218M 213M 9.36B 64.31M 56.22M 51.67M 48.16M 91.35M 6.12B 92.73M 620M 241M 3.01B 241M 236M 10.37B
Net income -6.26M -5.48M -5.03M -4.69M -8.9M -596M -9.03M -60.42M -23.49M -293M -23.51M -23.01M -1.01B -1.05M -918K -844K -786K -1.49M -99.97M -1.51M -10.13M -3.94M -49.14M -3.94M -3.86M -169M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
03/07/26 CA$4.200 -1.18% 1,901
02/07/26 CA$4.250 -3.63% 17,288
30/06/26 CA$4.410 +3.52% 323,319
29/06/26 CA$4.260 +2.90% 27,446
26/06/26 CA$4.140 -2.82% 7,800
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.957USD
Average target price
5.179USD
Spread / Average Target
+75.14%

Quarterly revenue - Rate of surprise